Sleep

Why Melatonin Is a Supplement Here and a Drug Abroad

Save

It seems strange that a hormone with real effects on the brain is sold like a vitamin. The explanation isn't about melatonin's safety data — it's about how US law classifies dietary supplements versus drugs, and what that classification does and doesn't require before a product reaches a shelf. Here is what that regulatory gap actually means for the evidence behind the bottle.

Last updated: July 2026

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

Why is melatonin available over the counter in the US?

Melatonin is sold over the counter in the United States because US law classifies it as a dietary supplement, not a drug, and that classification comes with a fundamentally different set of requirements. A prescription sleep medication has to complete a lengthy FDA review demonstrating both safety and effectiveness for a specific use before it can be sold. A dietary supplement does not: manufacturers can bring melatonin to market without proving in advance that it works for any particular purpose, as long as they do not make an explicit disease-treatment claim on the label.

That is a legal and regulatory distinction, not a scientific one. It says nothing about whether melatonin is safe or effective for a given use, only that the government has not required anyone to prove that before selling it, which is a very different bar than the one prescription sleep drugs have to clear. This is the same basic framework that governs vitamins, herbal products, and most other supplements sold in the US: the manufacturer, not a federal agency, is primarily responsible for a product's safety before it reaches a shelf, and enforcement action tends to happen after a problem is identified rather than before.

What FDA drug approval actually requires, and what a supplement skips

Prescription drug approval is not a one-time event; it comes with ongoing safety monitoring that continues long after a medication reaches the market. When new safety data emerged showing that morning blood levels of zolpidem could remain high enough to impair driving, the FDA required lower recommended doses specifically to address that risk 1. When reports accumulated of rare but serious injuries from complex sleep behaviors like sleepwalking and sleep-driving, the agency added a boxed warning across an entire class of prescription sleep drugs 2.

Prescription approval isn't just a hurdle at launch — it comes with continuous safety monitoring that can change how a drug is used years later.

A dietary supplement like melatonin has no equivalent mechanism. There is no premarket efficacy review to begin with, and post-market safety monitoring is far lighter than what applies to an approved drug, which is part of why quality and dosing accuracy can vary noticeably between bottles.

What the evidence shows for melatonin specifically

Being sold without premarket proof of effectiveness does not mean melatonin has no evidence behind it — it means the evidence exists separately from the regulatory approval process, and it turns out to be more limited than the supplement aisle suggests. A federal health agency's evidence summary credits melatonin with a real role in jet lag and delayed sleep-wake phase disorder, but concludes there is not enough strong evidence to recommend it for chronic insomnia 3. A major sleep-medicine guideline goes further, suggesting against relying on melatonin for chronic insomnia specifically because the trial evidence is too thin 4.

That combination — genuinely useful for a narrow circadian problem, weakly supported for the much more common complaint of ordinary insomnia — is easy to miss when a product sits on a shelf next to vitamins with no indication of how mixed its evidence actually is. That gap between a genuine circadian use and a much shakier insomnia use is easy to overlook on a supplement label, since US regulations do not require a product to specify which of those two very different situations its evidence actually supports.

Melatonin isn't the only supplement with this problem

The gap between how a product is sold and how well it is actually studied is not unique to melatonin. A meta-analysis of oral magnesium for insomnia in older adults found only a small reduction in the time it took to fall asleep, based on overall low-quality, uncertain evidence — a pattern of modest, uncertain benefit that shows up again and again across the supplement aisle 5. The same sleep-medicine guideline that cautions against relying on melatonin for chronic insomnia lists valerian and tryptophan in that same weak-evidence category 4, a reminder that the broader over-the-counter sleep aisle largely shares this pattern rather than melatonin being a special case. Melatonin happens to be the most visible example because it is the most widely used, not because its evidence is unusually weak or unusually strong relative to its supplement neighbors.

What this means for reading a bottle of melatonin

Because melatonin skips the premarket review a prescription drug undergoes, the practical burden of vetting a bottle falls more heavily on the person buying it. What's actually in melatonin supplements has been a documented concern, since supplement manufacturing is regulated far less tightly than prescription drug manufacturing, and the amount in a given product can differ from what the label states. Looking for third-party testing seals and buying from established manufacturers are reasonable, if imperfect, ways to close part of that gap, though none of it substitutes for the kind of premarket proof a prescription medication has to provide.

What's proven to work instead, for ongoing insomnia

For chronic insomnia specifically, as opposed to the circadian problems melatonin is genuinely suited to, the treatment with the strongest evidence is not a pill of any kind. A randomized trial comparing cognitive behavioral therapy for insomnia to the sleeping pill zopiclone in older adults found the behavioral treatment outperformed the medication on objective sleep measures, with gains that held up at follow-up while the pill's did not 6. That head-to-head result is a useful reminder that the regulatory question, is this a drug or a supplement, is separate from the more important question of what the evidence actually shows works, and for chronic insomnia the answer usually is not a bottle from either category. It also highlights something the regulatory conversation can obscure: the most effective option in that trial was neither the supplement nor the prescription drug, but a structured behavioral program that outperformed both.

Common questions

The FDA has some oversight of dietary supplements — it can act against products that are contaminated or falsely labeled — but that oversight is much lighter than the premarket safety and effectiveness review a prescription drug undergoes. Melatonin does not have to prove it works for a specific use before being sold, the way a prescription sleep medication does.

Different regulators classify melatonin differently. Some treat it as a hormone that requires a doctor's prescription, while US law places it in the dietary supplement category instead. The chemistry is the same everywhere; the regulatory classification, and what it requires before sale, is what differs from country to country.

Being sold over the counter reflects its regulatory classification, not a safety verdict. For short-term use in adults, melatonin is generally considered low-risk, but it can interact with some medications, and long-term safety data are limited. It has not been through the same premarket safety review as a prescription drug.

There is a related but distinct prescription medicine, ramelteon, that acts on the same melatonin receptors with more selectivity and went through the FDA's full drug-approval pathway. That is a different molecule with its own evidence base, not simply a stronger version of supplement melatonin, and it is discussed on its own page.

Because supplement manufacturing has looser oversight than prescription drug manufacturing, the actual melatonin content in a bottle can differ from what the label states. Looking for third-party testing certification is one practical way to narrow that gap, though it does not replace the kind of proof a prescription drug has to provide before approval.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

If things feel heavy, a person is available anytime — call or text 988.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

When to loop in a clinician about melatonin

  • —Insomnia most nights for three months or more that melatonin has not helped
  • —New confusion, unusual drowsiness, or a reaction after starting a melatonin product, especially in a young child
  • —Melatonin taken alongside a prescription medication without checking for interactions
  • —Insomnia accompanied by persistent low mood, anxiety, or thoughts of self-harm

If insomnia comes with thoughts of harming yourself, call or text 988 (the Suicide and Crisis Lifeline) any time; for a suspected overdose or severe allergic reaction, call 911.

This article is health education, not medical advice, and names no doses. Melatonin is a supplement, not reviewed for effectiveness before sale, and can interact with medications; persistent insomnia deserves evaluation by a clinician rather than long-term self-treatment.

References

  1. 1.US Food and Drug Administration (2013). Risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist). FDA Drug Safety Communication. link ✓FDA lowered recommended zolpidem doses in 2013 due to next-morning impairment risk; supports the example of ongoing post-approval regulatory oversight a prescription drug undergoes.
  2. 2.US Food and Drug Administration (2019). Certain Prescription Insomnia Medicines: New Boxed Warning — Due to Risk of Serious Injuries Caused by Sleepwalking, Sleep Driving and Engaging in Other Activities While Not Fully Awake. FDA Drug Safety Communication. link ✓FDA added a boxed warning to the z-drugs for complex sleep behaviors in 2019; supports the example of continuous post-market safety monitoring applied to approved prescription hypnotics.
  3. 3.National Center for Complementary and Integrative Health (2022). Melatonin: What You Need To Know. NCCIH, National Institutes of Health. link ✓NCCIH evidence summary: melatonin has a role in jet lag and delayed sleep-wake phase disorder but insufficient evidence for chronic insomnia; supports the mixed-evidence framing for melatonin.
  4. 4.Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL (2017). Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. Journal of Clinical Sleep Medicine. doi:10.5664/jcsm.6470 ✓AASM guideline suggests against melatonin for chronic insomnia due to insufficient evidence; supports the claim that guideline-level evidence for melatonin in ordinary insomnia is weak.
  5. 5.Mah J, Pitre T (2021). Oral magnesium supplementation for insomnia in older adults: a Systematic Review & Meta-Analysis. BMC Complementary Medicine and Therapies. doi:10.1186/s12906-021-03297-z ✓Meta-analysis of magnesium for insomnia finding a small effect on sleep onset but low-quality, uncertain evidence; supports the comparison that other supplements share melatonin's pattern of modest, uncertain benefit.
  6. 6.Sivertsen B, Omvik S, Pallesen S, et al. (2006). Cognitive Behavioral Therapy vs Zopiclone for Treatment of Chronic Primary Insomnia in Older Adults: A Randomized Controlled Trial. JAMA. doi:10.1001/jama.295.24.2851 ✓RCT finding CBT-I outperformed the sleeping pill zopiclone on objective sleep measures in older adults, with durable gains; supports CBT-I as the evidence-backed option for chronic insomnia regardless of drug-vs-supplement classification.

6 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — every citation independently verified. Editorial policy

← Back to the health library